The Scotland-based firm said that it will use the money for the development of its cancer tests and commercialization in new markets.

Of the 30 companies included, 19 companies saw their stock price increase, eight firms saw their share price decrease, and three companies remained essentially flat.

The QuickFinder COVID-19/Flu Antigen Self-Test and the QuickFinder COVID-19/Flu Antigen Pro Test detect SARS-CoV-2, influenza A, and influenza B in swab specimens and provide results within 15 minutes ...

Medix said the acquisition adds to its portfolio of raw materials used for in vitro diagnostics development and improves its ability to support immunoassay developers.

NEW YORK – Guardant Health announced Tuesday that its Guardant Reveal liquid biopsy test has received coverage from Medicare administrative contractor Palmetto GBA to monitor colorectal cancer ...

The partners plan to expand testing for early detection of childhood leukemias and lymphomas, bolster local testing capacity, and conduct a research study.

The Amsterdam-based biotech firm said that its melt curve analysis-based test is used as a first-tier genetic screening tool to aid the diagnosis of SMA.

Abbott reported $9.34 billion in diagnostics revenues in 2024, down 7 percent on a reported basis from $9.99 billion in 2023 and down 4 percent on an organic basis. Excluding COVID-19 testing-related ...

Last week, readers were most interested in a story about two Medicare administrative contractors delaying the implementation of a policy not to cover certain genetic tests.

The government alleges that BioReference submitted claims to federal healthcare programs for blood tests that were not ordered by a patient's provider.

The firm reported that its full-year 2024 revenues were up slightly as a rise in the diagnostics business was mostly offset by a decline in life sciences business.